- Researchers investigated the molecular mechanisms of deucravacitinib, a selective tyrosine kinase 2 inhibitor, in patients with systemic lupus erythematosus.
- This phase 2 trial analyzed blood transcriptome profiles from 363 patients and 56 healthy volunteers using RNA sequencing through week 32.
- Deucravacitinib modulated 2529 genes and significantly enriched dendritic cell populations compared to placebo while reverting myeloid cell gene sets toward normal.
- The researchers concluded that deucravacitinib successfully targets multiple pathogenic pathways, including interferon regulated genes and regulatory T cell gene sets.
- These findings support the continued evaluation of deucravacitinib in phase 3 clinical trials to validate its impact on immune mechanisms.
Precision Immunomodulation in Systemic Lupus Erythematosus
Managing systemic lupus erythematosus remains a significant clinical challenge due to the heterogeneous nature of its pathogenesis and the limitations of current standard-of-care therapies [1]. While traditional Janus kinase inhibitors have shown efficacy in various autoimmune conditions, they are often associated with broad immunosuppression and an increased risk of infections, particularly herpes zoster [2]. Tyrosine kinase 2 (TYK2) has emerged as a more specific therapeutic target because it selectively mediates signaling for type I interferons, interleukin-12, and interleukin-23, which are central to the lupus inflammatory cascade [3, 4]. In a phase 2 trial of 363 patients, the allosteric TYK2 inhibitor deucravacitinib at 3 mg twice daily achieved a Systemic Lupus Erythematosus Responder Index 4 (a composite measure of clinical improvement) response rate of 58 percent compared to 34 percent for placebo (p < 0.001) [5]. This treatment also significantly improved patient-reported outcomes, with fatigue scores decreasing by up to 7.3 points compared to a 3.4-point reduction in the placebo group [6]. A new post hoc analysis of these trial data using whole blood transcriptome profiling (a technique that measures the expression levels of all genes in the blood) now provides a detailed molecular map of how this targeted approach reshapes the immune landscape [7].
Defining the Molecular Baseline of Active Lupus
To establish a high-resolution molecular map of the disease state, the researchers conducted a transcriptomic analysis involving 363 patients with systemic lupus erythematosus and 56 healthy volunteers. This large cohort provided the statistical power necessary to utilize RNA sequencing (a method that quantifies the activity of thousands of genes simultaneously) to compare the blood of patients against a healthy baseline. By examining these samples, the study identified 527 differentially expressed genes (genes that are significantly more or less active in patients than in healthy individuals) at the start of the trial. These genetic differences were strictly defined by a log2 fold change greater than 1 and an adjusted P-value of less than .05, ensuring that the identified variations represented substantial and statistically robust deviations from normal physiology. For clinicians, mapping these baseline differences is crucial because it isolates the exact inflammatory pathways driving the disease before any therapeutic intervention occurs.
The baseline data revealed a complex immune environment characterized by specific cellular imbalances. Notably, the researchers found that regulatory T-cell gene sets were increased in patients with systemic lupus erythematosus compared to healthy volunteers at the beginning of the study. While regulatory T-cells (a subset of lymphocytes responsible for suppressing immune responses and maintaining self-tolerance) are typically associated with preventing autoimmunity, their elevated genetic signature in active lupus may reflect a compensatory but ultimately ineffective attempt by the body to control systemic inflammation. This molecular baseline serves as the essential framework for understanding how deucravacitinib subsequently modulates these pathogenic pathways and shifts the immune profile toward a more homeostatic state.
Transcriptomic Response to Selective TYK2 Inhibition
To evaluate the molecular effects of deucravacitinib over time, the researchers analyzed whole blood samples collected from patients between baseline and week 32. The pharmacodynamics of these genetic shifts were evaluated using linear mixed-effects models through a statistical software package known as DREAM (differential expression for repeated measures). This computational approach allowed the team to account for individual patient variations over the eight-month treatment period. The analysis revealed that deucravacitinib treatment modulated up to 2529 genes, representing a broad shift in the molecular landscape of the treated patients.
To interpret the functional significance of these genetic shifts, the authors employed single-sample gene set enrichment analysis (ssGSEA), a method that calculates a score for specific biological pathways in each individual sample rather than looking at genes in isolation. This analysis utilized standardized collections of genes known to function together in specific immune processes. The findings demonstrated that deucravacitinib modulated systemic lupus erythematosus-relevant gene sets, including interferon-regulated genes, which are central to the pathogenesis of the disease. Because tyrosine kinase 2 is a key signaling molecule for type I interferon receptors, these results provide direct evidence that the drug successfully targets the intended pathophysiologic pathways. For the practicing rheumatologist, this confirms that the clinical improvements seen with deucravacitinib are directly linked to the normalization of interferon signatures, addressing a primary driver of inflammation and tissue damage.
Cellular Rebalancing and Future Clinical Directions
To characterize the impact of tyrosine kinase 2 inhibition on the broader immune landscape, the researchers utilized a computational technique known as digital deconvolution via the xCell R package. This method allows investigators to estimate the relative abundance of different cell types within a mixed blood sample by analyzing specific gene expression patterns, effectively portraying cellular heterogeneity without the need for physical cell sorting. Through this approach, the study found that deucravacitinib treatment led to a significant enrichment of dendritic cell populations compared to the placebo group. This shift suggests a restructuring of the antigen-presenting environment, which is typically dysregulated in active disease.
The functional impact of these changes was further clarified by pathway analysis, which demonstrated that plasma cell gene sets decreased and myeloid cell gene sets reverted toward normal levels following deucravacitinib administration. For the clinician, this reversion of myeloid signatures is particularly relevant, as myeloid cells are primary producers of inflammatory cytokines and key drivers of end-organ damage in lupus. Furthermore, while regulatory T-cell gene sets were already elevated in patients at baseline, these levels further increased following treatment with deucravacitinib. This suggests an enhancement of the body's endogenous immunosuppressive mechanisms, potentially aiding in the restoration of immune tolerance. The analysis also identified variable, dose-dependent increases in naive and memory B lymphocytes, indicating that the drug influences B-cell maturation and trafficking pathways. Ultimately, these comprehensive transcriptomic findings provide a clear molecular rationale for the clinical efficacy observed in earlier trials. By successfully targeting multiple pathophysiologic immune mechanisms, these data support the continued evaluation of deucravacitinib in the phase 3 POETYK SLE trials, which will further define the role of selective tyrosine kinase 2 inhibition in the long-term management of systemic lupus erythematosus.
References
1. Xie L, Gomes LLA, Stone CJ, Faden D, Werth VP. An update on clinical trials for cutaneous lupus erythematosus. The Journal of Dermatology. 2024. doi:10.1111/1346-8138.17161
2. Isufi D, Jensen MB, Loft N, Skov L, Elberling J, Alinaghi F. Risk of infections during treatment with oral Janus kinase inhibitors in randomized placebo-controlled trials: A systematic review and meta-analysis. JAAD International. 2024. doi:10.1016/j.jdin.2024.09.012
3. Hu X, Li J, Fu M, Zhao X, Wang W. The JAK/STAT signaling pathway: from bench to clinic. Signal Transduction and Targeted Therapy. 2021. doi:10.1038/s41392-021-00791-1
4. Catlett IM, Gao L, Hu Y, Banerjee S, Krueger JG. Pharmacodynamic Response to Deucravacitinib, an Oral, Selective, Allosteric TYK2 Inhibitor, in a Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled Psoriasis Trial. Dermatology and Therapy. 2024. doi:10.1007/s13555-024-01262-5
5. Morand EF, Pike MC, Merrill JT, et al. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double‐Blind, Placebo‐Controlled Trial. Arthritis & Rheumatology. 2022. doi:10.1002/art.42391
6. Mosca M, Arnaud L, Askanase A, et al. Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial. Lupus Science & Medicine. 2025. doi:10.1136/lupus-2025-001517
7. Vital E, Wu C, Kahlenberg JM, et al. Whole blood transcriptome profiling in patients treated with deucravacitinib and novel mechanistic insights into TYK2 inhibition in lupus: results from a post hoc analysis of the PAISLEY SLE phase 2 trial.. Annals of the rheumatic diseases. 2026. doi:10.1016/j.ard.2026.02.007